Fingerprint
Dive into the research topics where Hella Danø is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Research output
- 9 Journal article
-
A direct comparison of classical oral Navelbine vs metronomic Navelbine in metastatic breast cancer: results from the Danish Breast Cancer Group's (DBCG) NAME-trial
Brems-Eskildsen, A. S., Kenholm, J., Brixen, A. T., Rønlev, J. D., Stenbygaard, L., Danø, H., Grunnet, M., Jakobsen, E. H., Neimann, J., Langkjer, S. T. & Geisler, J., Sept 2025, In: Breast Cancer Research and Treatment. 213, 2, p. 237-246 10 p.Research output: Contribution to journal › Journal article › Research › peer-review
-
Adjuvant Docetaxel and Cyclophosphamide With or Without Epirubicin for Early Breast Cancer: Final Analysis of the Randomized DBCG 07-READ Trial
Jensen, M.-B., Balslev, E., Knoop, A. S., Tuxen, M. K., Højris, I., Jakobsen, E. H., Cold, S., Danø, H., Glavicic, V., Kenholm, J. & Ejlertsen, B., 1 Feb 2025, In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 43, 4, p. 373-380 8 p.Research output: Contribution to journal › Journal article › Research › peer-review
5 Citations (Scopus) -
Prognostic Value of Pre-treatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer
Andersen, H. H., Bojesen, S. E., Johansen, J. S., Ejlertsen, B., Berg, T., Tuxen, M., Madsen, K., Danø, H., Flyger, H., Jensen, M.-B. & Nielsen, D. L., 1 May 2024, In: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 33, 5, p. 662-670 9 p.Research output: Contribution to journal › Journal article › Research › peer-review
2 Citations (Scopus) -
Metronomic treatment of vinorelbine with oral capecitabine is tolerable in the randomized Phase 2 study XeNa including patients with HER2 non-amplified metastatic breast cancer
Brems-Eskildsen, A. S., Linnet, S., Danø, H., Luczak, A., Vestlev, P. M., Jakobsen, E. H., Neimann, J., Jensen, C. B., Dongsgaard, T. & Langkjer, S. T., Feb 2021, In: Acta Oncologica. 60, 2, p. 157-164 8 p.Research output: Contribution to journal › Journal article › Research › peer-review
13 Citations (Scopus) -
Prediction of fulvestrant efficacy in patients with advanced breast cancer: retrospective-prospective evaluation of the predictive potential of a multigene expression assay
Christensen, T. D., Buhl, A. S. K., Christensen, I. J., Buhl, I. K., Balslev, E., Knoop, A. S., Danø, H., Glavicic, V., Luczak, A., Langkjer, S. T., Linnet, S., Jakobsen, E. H., Bogovic, J., Ejlertsen, B., Rasmussen, A., Hansen, A., Knudsen, S., Jensen, P. B. & Nielsen, D., Mar 2020, In: Breast Cancer: Basic and Clinical Research. 27, 2, p. 266-276 11 p.Research output: Contribution to journal › Journal article › Research › peer-review
2 Citations (Scopus)